Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
Interest Income Expense
Iterum Therapeutics PLC
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Interest Income Expense
$9.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Perrigo Company PLC
NYSE:PRGO
|
Interest Income Expense
-$176.1m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Interest Income Expense
-$277.6m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-24%
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Interest Income Expense
-$9.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-16%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Interest Income Expense
$2.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Interest Income Expense
-€4.5m
|
CAGR 3-Years
31%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
See Also
What is Iterum Therapeutics PLC's Interest Income Expense?
Interest Income Expense
9.6m
USD
Based on the financial report for Dec 31, 2023, Iterum Therapeutics PLC's Interest Income Expense amounts to 9.6m USD.
What is Iterum Therapeutics PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
211%
Over the last year, the Interest Income Expense growth was 211%.